Meningococcal infection – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 12:26:40 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Meningococcal infection – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of rMenB+OMV NZ meningococcal group B vaccine immune response and safety in previously vaccinated healthy participants aged 10 to 20 years https://clinicaltrials.eu/trial/study-of-rmenbomv-nz-meningococcal-group-b-vaccine-immune-response-and-safety-in-previously-vaccinated-healthy-participants-aged-10-to-20-years/ Wed, 29 Apr 2026 15:06:59 +0000 https://clinicaltrials.eu/trial/study-of-rmenbomv-nz-meningococcal-group-b-vaccine-immune-response-and-safety-in-previously-vaccinated-healthy-participants-aged-10-to-20-years/ This clinical trial evaluates the immune response to Bexsero, a vaccine against invasive meningococcal disease caused by group B bacteria. The study focuses on individuals aged 10 to 20 years who previously received this vaccine in early childhood. Meningococcal disease is a serious infection that can cause inflammation of the membranes surrounding the brain and spinal cord.

The vaccine is given as a suspension for intramuscular injection using a pre-filled syringe. Each participant will receive one dose of 0.5 milliliters of the vaccine. The study compares the immune response between people who received the vaccine in early childhood and those who have never received it before.

The main purpose is to determine if people previously vaccinated with Bexsero show a stronger immune response to a booster dose compared to those receiving the vaccine for the first time. The study will monitor participants for 31 days after vaccination to assess both the immune response and safety of the vaccine.

]]> Study on the Safety and Immune Response of MenACYW Conjugate Vaccine Compared to a Drug Combination in Healthy Infants and Toddlers https://clinicaltrials.eu/trial/study-on-the-safety-and-immune-response-of-menacyw-conjugate-vaccine-compared-to-a-drug-combination-in-healthy-infants-and-toddlers/ Wed, 29 Apr 2026 15:05:20 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-immune-response-of-menacyw-conjugate-vaccine-compared-to-a-drug-combination-in-healthy-infants-and-toddlers/ This clinical trial is focused on studying the effectiveness and safety of a vaccine for preventing meningococcal infection in healthy infants and toddlers. Meningococcal infection is a serious illness caused by bacteria that can lead to infections in the brain and spinal cord. The study involves two vaccines: the MenQuadfi vaccine and the Nimenrix vaccine. Both vaccines are designed to protect against four groups of the bacteria: A, C, W, and Y. The purpose of the study is to compare the immune response generated by these vaccines when given to infants at 6 months and again at 12 months.

Participants in the study will receive two doses of either the MenQuadfi vaccine or the Nimenrix vaccine. The first dose will be administered when the infants are between 6 and 7 months old, and the second dose will be given when they are between 12 and 13 months old. The study will monitor the levels of antibodies, which are proteins in the blood that help fight infections, to see how well the vaccines work. The study will also track any side effects or reactions to the vaccines to ensure they are safe for use in young children.

The trial aims to demonstrate that the MenQuadfi vaccine is not less effective than the Nimenrix vaccine in producing an immune response. This will be measured by looking at the levels of antibodies in the blood after vaccination. The study will also observe any immediate or delayed reactions to the vaccines, including any serious adverse events. The results of this study will help determine the best vaccination strategy for protecting young children against meningococcal infection.

]]>